Abstract:Cancer is associated with a high degree of heterogeneity, encompassing both inter- and intra-tumor heterogeneity, along with considerable variability in clinical response to common treatments across patients. Conventional models for tumor research, such as in vitro cell cultures and in vivo animal models, demonstrate significant limitations that fall short of satisfying the research requisites. Patient-derived tumor organoids, which recapitulate the structures, specific functions, molecular characteristics, genomics alterations and expression profiles of primary tumors. They have been efficaciously implemented in illness portrayal, mechanism exploration, high-throughput drug screening and assessment, discovery of innovative therapeutic targets and potential compounds, and customized treatment regimen for cancer patients. In contrast to conventional models, tumor organoids offer an intuitive, dependable, and efficient in vitro research model by conserving the phenotypic, genetic diversity, and mutational attributes of the originating tumor. Nevertheless, the organoid technology also confronts the bottlenecks and challenges, such as how to comprehensively reflect intra-tumor heterogeneity, tumor microenvironment, tumor angiogenesis, reduce research costs, and establish standardized construction processes while retaining reliability. This review extensively examines the use of tumor organoid techniques in fundamental research and precision medicine. It emphasizes the importance of patient-derived tumor organoid biobanks for drug development, screening, safety evaluation, and personalized medicine. Additionally, it evaluates the application of organoid technology as an experimental tumor model to better understand the molecular mechanisms of tumor. The intent of this review is to explicate the significance of tumor organoids in cancer research and to present new avenues for the future of tumor research.

Patient-derived Organoids in Translational Oncology and Drug Screening

Patient-derived organoids in precision cancer medicine

Patient‐derived Cancer Organoids for Drug Screening: Basic Technology and Clinical Application

Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients

Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Cancer organoids: A platform in basic and translational research

Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models

Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

Recent advances in patient‐derived tumor organoids for reconstructing TME of head and neck cancer

Organoids: approaches and utility in cancer research

Tumor Organoids for Cancer Research and Personalized Medicine

Organoids: An intermediate modeling platform in precision oncology.

Organoids for Cancer Research: Advances and Challenges

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Patient-derived organoids: a promising tool for breast cancer research

Organoid in Colorectal Cancer: Progress and Challenges